![Dragan Cicic](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dragan Cicic
Corporate Officer/Principal bei
SELLAS LIFE SCIENCES GROUP, INC.
Vermögen: 1 Mio $ am 31.05.2026
Profil
Dragan Cicic is currently a Member at the American Society of Hematology and Chief Development Officer & Senior Vice President at SELLAS Life Sciences Group, Inc. since 2024.
Former positions include Director, Chief Operating & Medical Officer at Actinium Pharmaceuticals, Inc. (2012–2013), Project Director at QED Technologies International, Inc., Chief Operating & Medical Officer at Cactus Ventures, Inc. (2012–2013), Principal at British Broadcasting Corp., Chief Technology Officer at Actinium Pharmaceuticals, Inc. (2017), and Senior Vice President at KLUS Pharma, Inc. Education includes a doctorate from the University of Belgrade, an MBA from The Wharton School of the University of Pennsylvania, and a doctorate from the School of Medicine (RS).
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.04.2026 | 126’443 ( 0.07% ) | 1 Mio $ | 31.05.2026 |
Aktive Positionen von Dragan Cicic
| Unternehmen | Position | Beginn |
|---|---|---|
| SELLAS LIFE SCIENCES GROUP, INC. | Corporate Officer/Principal | - |
American Society of Hematology
 American Society of Hematology Miscellaneous Commercial ServicesCommercial Services Operates as a hematology membership organisation | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Dragan Cicic
| Unternehmen | Position | Ende |
|---|---|---|
| ACTINIUM PHARMACEUTICALS, INC. | Vorstandsvorsitzender | - |
Actinium Pharmaceuticals, Inc. /Old/
 Actinium Pharmaceuticals, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Develops and commercializes alpha particle immunotherapeutics | Technik-/Wissenschafts-/F&E-Leiter | 18.04.2013 |
Cactus Ventures, Inc.
 Cactus Ventures, Inc. Financial ConglomeratesFinance Operates as a blank check company | Geschäftsführer | 18.04.2013 |
KLUS Pharma, Inc.
 KLUS Pharma, Inc. BiotechnologyHealth Technology Engages in discovery and development of novel and safer antibody-based therapeutics | Corporate Officer/Principal | - |
British Broadcasting Corp.
 British Broadcasting Corp. BroadcastingConsumer Services Provides television and radio broadcasting & digital media services | Corporate Officer/Principal | - |
Ausbildung von Dragan Cicic
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
60
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
Actinium Pharmaceuticals, Inc. /Old/
Actinium Pharmaceuticals, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Develops and commercializes alpha particle immunotherapeutics | Commercial Services |
Cactus Ventures, Inc.
Cactus Ventures, Inc. Financial ConglomeratesFinance Operates as a blank check company | Finance |
British Broadcasting Corp.
British Broadcasting Corp. BroadcastingConsumer Services Provides television and radio broadcasting & digital media services | Consumer Services |
University of Belgrade
 University of Belgrade Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
QED Technologies International, Inc.
 QED Technologies International, Inc. SemiconductorsElectronic Technology Develops polishing and metrology technology for semiconductors | Electronic Technology |
American Society of Hematology
American Society of Hematology Miscellaneous Commercial ServicesCommercial Services Operates as a hematology membership organisation | Commercial Services |
Actinium Pharmaceuticals, Inc.
 Actinium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers | Health Technology |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
School of Medicine (RS)
 School of Medicine (RS) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SELLAS Life Sciences Group, Inc.
 SELLAS Life Sciences Group, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
KLUS Pharma, Inc.
KLUS Pharma, Inc. BiotechnologyHealth Technology Engages in discovery and development of novel and safer antibody-based therapeutics | Health Technology |
